Clinical Trials
20 trialsNCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02921022 2025-11-26
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT01959139 2024-02-09
S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Phase 1/2 Completed
NCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT02715804 2020-07-14
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Halozyme Therapeutics
Phase 3 Terminated
NCT02753595 2020-07-13
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Eisai Inc.
Phase 1/2 Terminated
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02563548 2020-02-07
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Halozyme Therapeutics
Phase 1 Completed
NCT03267940 2020-02-07
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Halozyme Therapeutics
Phase 1 Terminated
NCT04134468 2020-01-31
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT03481920 2019-08-22
A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
PH Research, S.L.
Phase EARLY_PHASE1 Terminated
NCT03634332 2019-05-07
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Pancreatic Cancer Research Team
Phase 2 Unknown
NCT02910882 2019-04-11
HALO-IST
Scripps Health
Phase 2 Terminated
NCT02346370 2019-02-08
PRIMAL
Halozyme Therapeutics
Phase 1 Terminated
NCT01453153 2018-11-30
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02241187 2017-09-27
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01170897 2014-01-29
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
Halozyme Therapeutics
Phase 1 Completed
NCT00834704 2013-03-26
PEG
Halozyme Therapeutics
Phase 1 Completed